Biopharmaceutical company developing protein-based therapies for metabolic diseases, with a focus on orally delivered therapeutics that act locally in the gastrointestinal tract
Biopharmaceutical company developing protein-based therapies for metabolic diseases, with a focus on orally delivered therapeutics that act locally in the gastrointestinal tract. Its lead candidate, liprotamase, is a non-porcine pancreatic enzyme replacement therapy under FDA review for exocrine pancreatic insufficiency, including EPI associated with cystic fibrosis.